Callan Capital, LLC Tarsus Pharmaceuticals, Inc. Transaction History
Callan Capital, LLC
- $1.2 Billion
- Q2 2024
A detailed history of Callan Capital, LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 14,800 shares of TARS stock, worth $490,620. This represents 0.03% of its overall portfolio holdings.
Number of Shares
14,800
Previous 14,000
5.71%
Holding current value
$490,620
Previous $508,000
20.87%
% of portfolio
0.03%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding TARS
# of Institutions
155Shares Held
40.4MCall Options Held
37.9KPut Options Held
808K-
Rtw Investments, LP New York, NY3.41MShares$113 Million1.55% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$108 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$80.7 Million2.68% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$74.7 Million7.48% of portfolio
-
Cowen And Company, LLC2.2MShares$72.8 Million1.53% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $884M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...